A decade of innovation in pharmaceutical R&D: the Chorus model
- PMID: 25503514
- DOI: 10.1038/nrd4497
A decade of innovation in pharmaceutical R&D: the Chorus model
Abstract
Chorus is a small, operationally independent clinical development organization within Eli Lilly and Company that specializes in drug development from candidate selection to clinical proof of concept. The mission of Chorus is to achieve proof of concept rapidly and at a low cost while positioning successful projects for 'pharma-quality' late-stage development. Chorus uses a small internal staff of experienced drug developers and a network of external vendors to design and implement chemistry, manufacturing and control processes, preclinical toxicology and biology, and Phase I/II clinical trials. In the decade since it was established, Chorus has demonstrated substantial productivity improvements in both time and cost compared to traditional pharmaceutical research and development. Here, we describe its development philosophy, organizational structure, operational model and results to date.
Similar articles
-
How should we support pharmaceutical innovation?Expert Rev Pharmacoecon Outcomes Res. 2009 Aug;9(4):313-20. doi: 10.1586/erp.09.34. Expert Rev Pharmacoecon Outcomes Res. 2009. PMID: 19670991
-
Models for open innovation in the pharmaceutical industry.Drug Discov Today. 2013 Dec;18(23-24):1133-7. doi: 10.1016/j.drudis.2013.07.013. Epub 2013 Jul 26. Drug Discov Today. 2013. PMID: 23892183
-
Accessing external innovation in drug discovery and development.Expert Opin Drug Discov. 2015 Jun;10(6):579-89. doi: 10.1517/17460441.2015.1040759. Epub 2015 Apr 24. Expert Opin Drug Discov. 2015. PMID: 25910932 Review.
-
Reviving an R&D pipeline: a step change in the Phase II success rate.Drug Discov Today. 2021 Feb;26(2):308-314. doi: 10.1016/j.drudis.2020.10.019. Epub 2020 Oct 28. Drug Discov Today. 2021. PMID: 33129994 Review.
-
Alterations in processes and priorities needed for new drug development.Ann Intern Med. 2006 Nov 21;145(10):793-6. doi: 10.7326/0003-4819-145-10-200611210-00024. Ann Intern Med. 2006. PMID: 17116936 No abstract available.
Cited by
-
Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.Pharmaceut Med. 2019 Jun;33(3):193-198. doi: 10.1007/s40290-019-00280-5. Pharmaceut Med. 2019. PMID: 31933287 Review.
-
Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work.Eur J Med Chem. 2019 Nov 15;182:111602. doi: 10.1016/j.ejmech.2019.111602. Epub 2019 Aug 8. Eur J Med Chem. 2019. PMID: 31421629 Free PMC article. Review.
-
Opportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big Data.Front Pharmacol. 2016 Dec 6;7:461. doi: 10.3389/fphar.2016.00461. eCollection 2016. Front Pharmacol. 2016. PMID: 27999543 Free PMC article. Review.
-
Expedited Safety Reporting to Sponsors Through the Implementation of an Alert System for Clinical Trial Management at an Academic Medical Center: Retrospective Design Study.JMIR Med Inform. 2020 Feb 23;8(2):e14379. doi: 10.2196/14379. JMIR Med Inform. 2020. PMID: 32130175 Free PMC article.
-
Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets.Biomedicines. 2016 Nov 21;4(4):27. doi: 10.3390/biomedicines4040027. Biomedicines. 2016. PMID: 28536394 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources